Curis, Inc.
CRIS
Rank in Stocks
#32638
Curis, Inc., a biotechnology company, engages in the discovery and development... Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The companyโs pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Share Price
$0.6976
Last synced: 2026-11-09
Market Cap
$1.36M
Change (1 day)
-23.04%
Change (1 year)
-97.21%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Curis, Inc. (CRIS)
Category
Healthcare
EPS for Curis, Inc. (CRIS)
EPS as of June 2026 TTM: $-14.22
According to Curis, Inc.'s latest financial reports, its current EPS (TTM) is $-14.22. At the end of 2025 the company had an EPS of $-11.60, an increase over its 2024 EPS of $-137.60.
EPS history for Curis, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-14.22 | 22.59% |
| 2025 | $-11.60 | -91.57% |
| 2024 | $-137.60 | -23.21% |
| 2023 | $-179.20 | -26.19% |
| 2022 | $-242.80 | 22.38% |
| 2021 | $-198.40 | -19.28% |
| 2020 | $-245.80 | -36.55% |
| 2019 | $-387.40 | -1.53% |
| 2018 | $-393.40 | -89.00% |
| 2017 | $-3.58K | 297.24% |
| 2016 | $-900.00 | -6.25% |
| 2015 | $-960.00 | 118.18% |
| 2014 | $-440.00 | 46.67% |
| 2013 | $-300.00 | -28.57% |
| 2012 | $-420.00 | 61.54% |
| 2011 | $-260.00 | 116.67% |
| 2010 | $-120.00 | -60.00% |
| 2009 | $-300.00 | -21.05% |
| 2008 | $-380.00 | 46.15% |
| 2007 | $-260.00 | -27.78% |
| 2006 | $-360.00 | -41.94% |
| 2005 | $-620.00 | -6.06% |
| 2004 | $-660.00 | 1,900.00% |
| 2003 | $-33.00 | -87.16% |
| 2002 | $-257.00 | -95.00% |
| 2001 | $-5.14K | -87.02% |
| 2000 | $-39.60K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -210.13% |
US
|
|
| $-7.07 | -50.28% |
US
|
|
| $-5.29 | -62.80% |
AU
|
|
| $12.88 | -190.58% |
BE
|
|
| $21.56 | -251.62% |
NL
|
Questions about Curis, Inc.'s earnings per share (EPS)
What is Curis, Inc.'s earnings per share (EPS)?
Curis, Inc.'s earnings per share (EPS) over the last twelve months is $-14.22, as of Jun 2026.
What was Curis, Inc.'s earnings per share (EPS) in 2025?
In 2025, Curis, Inc.'s earnings per share (EPS) was $-11.60, compared with $-137.60 in 2024.
How has Curis, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Curis, Inc.'s earnings per share (EPS) was highest in 2025 ($-11.60) and lowest in 2020 ($-245.80).
How does Curis, Inc.'s earnings per share (EPS) compare with similar companies?
Curis, Inc.'s earnings per share (EPS) ($-14.22) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.